Synthesis and biological activity of enantiomeric pairs of 5-vinylthiolactomycin congeners

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 14, 2007, Pages 4070-4074

  Ohata, Kohei ^a   Terashima, Shiro ^b  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

^b SAGAMI CHEMICAL RESEARCH CENTER   (Japan)

Author keywords

5 Vinylthiolactomycin; Antibiotic; Inhibitor of mammalian type I fatty acid synthase

Indexed keywords

3 NOR 5 (PENT 1 ENYL)THIOLACTOMYCIN DERIVATIVE; 3 NORTHIOLACTOMYCIN DERIVATIVE; 4 HYDROXY 5 METHYL 5 (PENT 1 ENYL) 5H THIOPHEN 2 ONE; 5 VINYLTHIOLACTOMYCIN DERIVATIVE; FATTY ACID SYNTHASE INHIBITOR; THIOLACTOMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEROIDES FRAGILIS; DRUG ACTIVITY; DRUG SYNTHESIS; ENANTIOMER; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MORAXELLA CATARRHALIS; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

MAMMALIA;

EID: 34250358676     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.067     Document Type: Article

References (32)

1. Oishi H., Noto T., Sasaki H., Suzuki K., Hayashi T., Okazaki H., Ando K., and Sawada M. J. Antibiot. 35 (1982) 391
2. Noto T., Miyakawa S., Oishi H., Endo H., and Okazaki H. J. Antibiot. 35 (1982) 401
3. Miyakawa S., Suzuki K., Noto T., Harada Y., and Okazaki H. J. Antibiot. 35 (1982) 411
4. Kremer L., Douglas J.D., Baulard A.R., Morehouse C., Guy M.R., Alland D., Dover L.G., Lakey J.H., Jacobs W.R., Brennan P.J., Minnikin D.E., and Besra G.S. J. Biol. Chem. 275 (2000) 16857
5. Slayden R.A., Lee R.E., Armour J.W., Cooper A.M., Orme I.M., Brennan P.J., and Besra G.S. Antimicrob. Agents Chemother. 40 (1996) 2813
6. Kim P., Zhang Y.-M., Shenoy G., Nguyen Q.-A., Boshoff H.I., Manjunatha U.H., Goodwin M.B., Lonsdale J., Price A.C., Miller D.J., Duncan K., White S.W., Rock C.O., Barry III C.E., and Dowd C.S. J. Med. Chem. 49 (2006) 159
7. Waller R.F., Ralph S.A., Reed M.B., Su V., Douglas J.D., Minnikin D.E., Cowman A.F., Besra G.S., and McFadden G.I. Antimicrob. Agents Chemother. 47 (2003) 297
8. Jones S.M., Urch J.E., Brun R., Harwood J.L., Berry C., and Gilbert I.H. Bioorg. Med. Chem. 12 (2004) 683
9. Jackowski S., Murphy C.M., Cronan J.E., and Rock C.O. J. Biol. Chem. 264 (1989) 7624
10. Price A.C., Choi K.-H., Heath R.J., Li Z., White S.W., and Rock C.O. J. Biol. Chem. 276 (2001) 6551
11. Hayashi T., Yamamoto O., Sasaki H., Kawaguchi A., and Okazaki H. Biochem. Biophys. Res. Commun. 115 (1983) 1108
12. Nishida I., Kawaguchi A., and Yamada M. J. Biochem. (Tokyo) 99 (1986) 1447
13. McFadden J.M., Medghalchi S.M., Thupari J.N., Pinn M.L., Vadlamudi A., Miller K.I., Kuhajda F.P., and Townsend C.A. J. Med. Chem. 48 (2005) 946
14. Sakya S.M., Suarez-Contreras M., Dirlam J.P., O'Connell T.N., Hayashi S.F., Santoro S.L., Kamicker B.J., George D.M., and Ziegler C.B. Bioorg. Med. Chem. Lett. 11 (2001) 2751
15. Senior S.J., Illarionov P.A., Gurcha S.S., Campbell I.B., Schaeffer M.L., Minnikin D.E., and Besra G.S. Bioorg. Med. Chem. Lett. 13 (2003) 3685
16. Senior S.J., Illarionov P.A., Gurcha S.S., Campbell I.B., Schaeffer M.L., Minnikin D.E., and Besra G.S. Bioorg. Med. Chem. Lett. 14 (2004) 373
17. Kamal A., Shaik A.A., Sinha R., Yadav J.S., and Arora S.K. Bioorg. Med. Chem. Lett. 15 (2005) 1927
18. Jones S.M., Urch J.E., Kaiser M., Brun R., Harwood J.L., Berry C., and Gilbert I.H. J. Med. Chem. 48 (2005) 5932
19. For the total synthesis of optically active thiolactomycin so far reported, See. Chambers M.S., and Thomas E.J. J. Chem. Soc. Chem. Commun. (1989) 23
20. Chambers M.S., and Thomas E.J. J. Chem. Soc. Perkin Trans. 1 (1997) 417
21. McFadden J.M., Frehywot G.L., and Townsend C.A. Org. Lett. 4 (2002) 3859
22. Totama K., Tanchi T., Mase N., Yoda H., and Takabe K. Tetrahedron Lett. 47 (2006) 7163
23. Kamal A., Shark A., Azeecla S., Malik M./S., and Sandbhor M. Tertrahedron Assymm. 17 (2006) 2890
24. Darmann K.L., and Bruckner R. Angew. Chem. Int. Ed. 46 (2007) 1160
25. Ohata K., and Terashima S. Tetrahedron Lett. 47 (2006) 2787
26. Kuhajda F.P., Pizer E.S., Li J.N., Mani S., Frehywot G.L., and Townsend C.A. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 3450
27. 10 asymmetric deconjugative α-sulfenylation of (S)-N-acyloxazolidin-2-one 6a-f prepared from (S)-4-benzyloxazolidin-2-one gave (R)-sulfenylated products 7a-f. The latter reaction carried out in the absence of HMPA was anticipated to proceed through the chelated (E)-dienolate (II) due to the absence of HMPA.{A figure is presented}
28. 1H NMR spectra of 7a and 7c-f similar to that of 7b. Based on these preliminary results, (S)-4-benzyloxazolidin-2-one was employed as a chiral auxiliary for preparing 3 and 4 instead of its (R)-enantiomer.
29. 15).
30. 1H NMR spectra, 7a >90%de; ent-7a >99%de; 7c >90%de; ent-7c >99%de; 7d >95%de; and ent-7d >95%de.
31. Determination of MICs by agar dilution methods was performed according to the guideline M7-A6 of the Clinical and Laboratory Standards Institute (2003).
32. 14C]acetate into cellular fatty acid as previously described with some modifications. See:. Murakami K., Tobe K., Ide T., Mochizuki T., Ohashi M., Akanuma Y., Yazaki Y., and Kadowaki T. Diabetes 47 (1998) 1841